DNA repair in cancer: Emerging targets for personalized therapy

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 77-92

  Abbotts, Rachel ^a   Thompson, Nicola ^a   Madhusudan, Srinivasan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Biomarker; Drug target; Synthetic lethality

Indexed keywords

EID: 84894317769     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S50497     Document Type: Article

References (151)

1. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-374.
2. Sweasy JB, Lang T, DiMaio D. Is base excision repair a tumor suppressor mechanism? Cell Cycle. 2006;5(3):250-259.
3. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513-1530.
4. Frosina G. Commentary: DNA base excision repair defects in human pathologies. Free Radic Res. 2004;38(10):1037-1054.
5. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275-292.
6. Madhusudan S, Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med. 2005;11(11):503-511.
7. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
8. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
9. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 1974;34(9):2311-2321.
10. Lambros MB, Natrajan R, Geyer FC, et al. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 2010;23(10):1334-1345.
11. Eker AP, Quayle C, Chaves I, van der Horst GT. DNA repair in mammalian cells: direct DNA damage reversal: elegant solutions for nasty problems. Cell Mol Life Sci. 2009;66(6):968-980.
12. Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol. 2010;8:38.
13. Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121(3):575-589.
14. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39-85.
15. Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, Dogliotti E. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie. 2003;85(11):1053-1071.
16. Nilsen H, Krokan HE. Base excision repair in a network of defence and tolerance. Carcinogenesis. 2001;22(7):987-998.
17. Izumi T, Wiederhold LR, Roy G, et al. Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage. Toxicology. 2003;193(1-2):43-65.
18. Dianov G, Allinson SL, Budworth H, Sleeth KM. Mammalian base excision repair. In: Caldecott KW, editor. Eukaryotic DNA Damage Surveillance and Repair. Kluwer Academic/Plenium Publishers; 2003:1-22.
19. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet. 2004;38:445-476.
20. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci. 2009;66(6):981-993.
21. Abbotts R, Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev. 2010;36(5):425-435.
22. Wilson DM 3rd, Kim D, Berquist BR, Sigurdson AJ. Variation in base excision repair capacity. Mutat Res. 2011;711(1-2):100-112.
23. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3(6):430-440.
24. Pommier Y, Redon C, Rao VA, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res. 2003;532(1-2):173-203.
25. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet. 2008;9(8):619-631.
26. Parlanti E, Locatelli G, Maga G, Dogliotti E. Human base excision repair complex is physically associated to DNA replication and cell cycle regulatory proteins. Nucleic Acids Res. 2007;35(5):1569-1577.
27. Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007;27(3):1007-1016.
28. Chen D, Yu Z, Zhu Z, Lopez CD. E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair. J Biol Chem. 2008;283(22): 15381-15389.
29. Sugasawa K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat Res. 2010;685(1-2): 29-37.
30. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res. 2008;18(1):64-72.
31. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis. 2000;21(3):453-460.
32. Iorns E, Lord CJ, Grigoriadis A, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One. 2009;4(4):e5120.
33. Sourisseau T, Maniotis D, McCarthy A, et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. Embo Mol Med. 2010;2(4):130-142.
34. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85-98.
35. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010;7(4):197-208.
36. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res. 2010;16(21):5107-5113.
37. Martin SA, Hewish M, Lord CJ, Ashworth A. Genomic instability and the selection of treatments for cancer. J Pathol. 2010;220(2):281-289.
38. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. Embo Mol Med. 2009;1(6-7):315-322.
39. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J. 2009;417(3):639-650.
40. Kass EM, Jasin M. Collaboration and competition between DNA double-strand break repair pathways. FEBS Lett. 2010;584(17):3703-3708.
41. Mladenov E, Iliakis G. Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. Mutat Res. 2011;711(1-2):61-72.
42. McVey M, Lee SE. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet. 2008;24(11):529-538.
43. de Villartay JP. V(D)J recombination deficiencies. Adv Exp Med Biol. 2009;650:46-58.
44. Nussenzweig A, Nussenzweig MC. A backup DNA repair pathway moves to the forefront. Cell. 2007;131(2):223-225.
45. Katsura Y, Sasaki S, Sato M, et al. Involvement of Ku80 in microhomology-mediated end joining for DNA double-strand breaks in vivo. DNA Repair (Amst). 2007;6(5):639-648.
46. Schipler A, Iliakis G. DNA double-strand-break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice. Nucleic Acids Res. 2013;41(16): 7589-7605.
47. Kavanagh JN, Redmond KM, Schettino G, Prise KM. DNA double strand break repair: a radiation perspective. Antioxid Redox Signal. 2013;18(18):2458-2472.
48. Shi L, Oberdoerffer P. Chromatin dynamics in DNA double-strand break repair. Biochim Biophys Acta. 2012;1819(7):811-819.
49. Murray JM, Stiff T, Jeggo PA. DNA double-strand break repair within heterochromatic regions. Biochem Soc Trans. 2012;40(1):173-178.
50. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181-211.
51. Kobayashi J, Iwabuchi K, Miyagawa K, et al. Current topics in DNA double-strand break repair. J Radiat Res. 2008;49(2):93-103.
52. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst). 2007;6(7):923-935.
53. Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet. 2006;40:363-383.
54. Cahill D, Connor B, Carney JP. Mechanisms of eukaryotic DNA double strand break repair. Front Biosci. 2006;11:1958-1976.
55. van den Bosch M, Lohman PH, Pastink A. DNA double-strand break repair by homologous recombination. Biol Chem. 2002;383(6): 873-892.
56. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev. 2000;10(2):144-150.
57. Featherstone C, Jackson SP. DNA double-strand break repair. Curr Biol. 1999;9(20):R759-R761.
58. Hanada K, Ikeda H. [Double strand break repair via DNA end-joining]. Tanpakushitsu Kakusan Koso. 1999;44(Suppl 12):1838-1844. Japanese.
59. Kanaar R, Hoeijmakers JH, van Gent DC. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 1998;8(12):483-489.
60. Tsukamoto Y, Ikeda H. Double-strand break repair mediated by DNA end-joining. Genes Cells. 1998;3(3):135-144.
61. Sargent RG, Brenneman MA, Wilson JH. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol Cell Biol. 1997;17(1):267-277.
62. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol. 2005;25(16):7158-7169.
63. Lawley PD, Phillips DH. DNA adducts from chemotherapeutic agents. Mutat Res. 1996;355(1-2):13-40.
64. Bogliolo M, Schuster B, Stoepker C, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet. 2013;92(5):800-806.
65. Kumaresan KR, Sridharan DM, McMahon LW, Lambert MW. Deficiency in incisions produced by XPF at the site of a DNA interstrand cross-link in Fanconi anemia cells. Biochemistry. 2007;46(50):14359-14368.
66. Ho TV, Scharer OD. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ Mol Mutagen. 2010;51(6): 552-566.
67. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2(8):483-490.
68. Hinz JM. Role of homologous recombination in DNA interstrand crosslink repair. Environ Mol Mutagen. 2010;51(6):582-603.
69. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11(7):467-480.
70. Long DT, Raschle M, Joukov V, Walter JC. Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science. 2011;333(6038): 84-87.
71. Nicolay NH, Helleday T, Sharma RA. Biological relevance of DNA polymerase beta and translesion synthesis polymerases to cancer and its treatment. Curr Mol Pharmacol. 2012;5(1):54-67.
72. Yamanaka K, Lloyd RS. Functions of translesion DNA polymerases: implications for cancer risk and opportunities as therapeutic targets. In: Madhusudan S, Wilson DM 3rd, editors. DNA Repair and Cancer: from Bench to Clinic. Boca Raton, USA: CRC Press; 2013.
73. McCulloch SD, Kunkel TA. The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res. 2008;18(1):148-161.
74. Higgins NP, Kato K, Strauss B. A model for replication repair in mammalian cells. J Mol Biol. 1976;101(3):417-425.
75. Long DT, Kreuzer KN. Fork regression is an active helicase-driven pathway in bacteriophage T4. Embo Rep. 2009;10(4):394-399.
76. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci. 2003;116(Pt 20):4077-4085.
77. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicol. 2002;181-182:475-481.
78. Yamtich J, Nemec AA, Keh A, Sweasy JB. A germline polymorphism of DNA polymerase beta induces genomic instability and cellular transformation. PLoS Genet. 2012;8(11):e1003052.
79. Starcevic D, Dalal S, Sweasy JB. Is there a link between DNA polymerase beta and cancer? Cell Cycle. 2004;3(8):998-1001.
80. Bapat A, Fishel M, Kelley MR. Going ape as an approach to cancer therapeutics. Antioxid Redox Signal. 2009;11(3):651-668.
81. Basu B, Yap TA, Molife LR, de Bono JS. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol. 2012;24(3):316-324.
82. Megnin-Chanet F, Bollet MA, Hall J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci. 2010;67(21): 3649-3662.
83. Mizuarai S, Kotani H. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet. 2010;128(6):567-575.
84. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728-2737.
85. Ossovskaya V, Li L, Bradley C, Sherman B. Abstract 2311: activity of BSI-201, a potent poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts. 99th AACR Annual Meeting; 2008; San Diego, CA.
86. Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem. 2012;19(23): 3907-3921.
87. Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). In: ASCO Annual Meeting. Atlanta, GA; J Clin Oncol. 2006;24:Abstract 8013.
88. AstraZeneca. Efficacy and safety study of olaparib in combination with paclitaxel to treat advanced gastric cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01924533.NLM identifier: NCT01924533. Accessed August 26, 2013.
89. Sanofi-aventis. Sanofi-aventis reports top-line results from phase III study with BSI-201 in metastatic triple-negative breast cancer [press release]. Paris, France: Sanofi-aventis; January 27, 2011. Available from: http://en.sanofi.com/Images/13666_20110127_BSI_en.pdf. Accessed August 26, 2013.
90. Sanofi-aventis. Sanofi provides update on phase 3 studies of two investigational compounds [press release]. Paris, France: Sanofi-aventis; June 3, 2013. Available from: http://en.sanofi.com/Images/33127_20130603_rdupdate_en.pdf. Accessed August 26, 2013.
91. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012;18(2):510-523.
92. Glendenning J, Tutt A. PARP inhibitors - current status and the walk towards early breast cancer. Breast. 2011;20 Suppl 3:S12-S19.
93. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol. 2010;7(12):718-724.
94. Tuma RS. Combining carefully selected drug, patient genetics may lead to total tumor death. J Natl Cancer Inst. 2007;99(20):1505-1506, 1509.
95. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Phamacol. 2008;8(4):363-369.
96. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
97. Miki Y, Swensen J, Shattuckeidens D, et al. A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
98. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171-182.
99. Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010;70(13):5389-5398.
100. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature. 1980;283(5747):593-596.
101. Strom CE, Johansson F, Uhlen M, Szigyarto CA, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011;39(8):3166-3175.
102. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588-5599.
103. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387-393.
104. Balmana J, Domchek SM, Tutt A, Garber JE. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 2011;1(1):29-34.
105. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
106. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
107. AstraZeneca. Olaparib monotherapy in patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01844986. NLM identifier: NCT01844986 Accessed June 14, 2013.
108. AstraZeneca. Olaparib treatment in BRCA mutated ovarian cancer patients after complete or partial response to platinum chemotherapy. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01874353. NLM identifier: NCT01874353. Accessed August 26, 2013.
109. Drew Y, Ledermann JA, Jones A, et al. Abstract 3104: Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. ASCO Annual Meeting. Chicago, IL: J Clin Oncol. 2011;29:3104.
110. Schelman WR, Sandhu SK, Moreno Garcia V, et al. First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (SOC). ASCO Annual Meeting. Chicago, IL: J Clin Oncol. 2011;29:Abstract 3102.
111. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-819.
112. Giorgetti G, Galizia E, Bianchi F, et al. Brcaness phenotype and methylation of BRCA1 promoter in sporadic breast cancers. Ann Oncol. 2007;18:52-52.
113. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570-3576.
114. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
115. AstraZeneca. AstraZeneca updates on olaparib and TC-5214 development programmes [press release]. London, UK: AstraZeneca; December 20, 2011. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development. Accessed August 29, 2012.
116. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111-1115.
117. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116-1120.
118. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688-695.
119. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879-882.
120. Williamson CT, Kubota E, Hamill JD, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. Embo Mol Med. 2012;4(6):515-527.
121. Sultana R, McNeill DR, Abbotts R, et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer. 2012;131(10):2433-2444.
122. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011;71(7):2632-2642.
123. Kurosawa A, Saito S, So S, et al. DNA ligase IV and artemis act cooperatively to suppress homologous recombination in human cells: implications for DNA double-strand break repair. PLoS One. 2013;8(8):e72253.
124. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther. 2010;9(6): 1775-1787.
125. Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst). 2008;7(12): 2010-2019.
126. Sultana R, Abdel-Fatah T, Abbotts R, et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013;73(5):1621-1634.
127. Seo Y, Kinsella TJ. Essential role of DNA base excision repair on survival in an acidic tumor microenvironment. Cancer Res. 2009;69(18): 7285-7293.
128. Bindra RS, Gibson SL, Meng A, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 2005;65(24): 11597-11604.
129. Bindra RS, Schaffer PJ, Meng A, et al. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci. 2005;1059: 184-195.
130. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010;17(3):235-248.
131. Gupta A, Yang Q, Pandita RK, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009;8(14):2198-2210.
132. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7(2):193-204.
133. Shen WH, Balajee AS, Wang JL, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157-170.
134. Ming M, He YY. PTEN in DNA damage repair. Cancer Lett. 2013; 319(2):125-129.
135. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008;27(41):5443-5453.
136. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci. 2008;121(Pt 3):249-253.
137. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010;2(53):53-75.
138. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010;70(13):5457-5464.
139. Fraser M, Zhao H, Luoto KR, et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res. 2012;18(4): 1015-1027.
140. Minami D, Takigawa N, Takeda H, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013;11(2):140-148.
141. Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One. 2013;8(4):e60408.
142. Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol. 2011;8(5):302-306.
143. Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther. 2007;14(6):543-549.
144. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-892.
145. Mereniuk TR, El Gendy MA, Mendes-Pereira AM, et al. Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Mol Cancer Ther. 2013;12(10):2135-2144.
146. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123(1):189-196.
147. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
148. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010;16(8): 2344-2351.
149. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581-6591.
150. Lubbers LS, Rowe BA, Hodge LM, et al. PISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ. J Pharmacol Toxicol Methods. 2010;61(3): 319-328.
151. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14(23):7917-7923.